Introduction {#Sec1}
============

Although whole breast irradiation remains the standard of care after conservative surgery for early stage breast cancer, partial breast irradiation (PBI), namely the irradiation of only the breast tissue surrounding the lumpectomy cavity, is emerging. The recent publication of the American Society for Radiation Oncology (ASTRO) consensus statement gave a further stimulus to the spread of PBI in clinical practice \[[@CR1]\].

The most used fractionation scheme is that proposed by Vicini at al., who explored in a phase II trial the safety and efficacy of 38.5 Gy at 3.85 Gy/fraction delivered 2 fractions per day with three dimensional conformal external beam radiotherapy (3D-CRT) \[[@CR2]\]. This fractionation was then adopted also by the Radiation Therapy Oncology Group (RTOG): the RTOG 0319 study documented that delivering 38.5 Gy in 5 days, 2 fractions per day, is safe, and the toxicity profile is low \[[@CR3]\].

Due to the fact that some studies reported poor cosmetic and toxicity results using the above-mentioned radiotherapy schedule \[[@CR4], [@CR5]\], we treated our patients with PBI using a once daily fractionation scheme consisting of 40 Gy in 10 fractions, and we documented an excellent toxicity profile \[[@CR6]\]. We therefore decided to continue to accelerate the radiation delivery, according to previously published radiobiological models \[[@CR7], [@CR8]\].

The purpose of the present study is to assess prospectively the efficacy and toxicity in breast cancer patients treated who underwent PBI with a schedule consisting of 35 Gy in 7 daily fractions (5 Gy per fraction).

Materials and Methods {#Sec2}
=====================

Patients {#Sec3}
--------

Between July 2011 and December 2013 patients affected by early stage breast cancer, who had breast conservative surgery were enrolled in this phase II prospective trial. Both the approval from our institutional review board and written informed consent from the patients were obtained.

To be included in this study patients had to be 60 years old or over and treated with breast conservative surgery for early stage (pT1-T2 pN0-N1a) invasive ductal (IDC) or lobular carcinoma (ILC). Patients were required to have negative surgical margins; re-excision was allowed in case of positive margins. Biopsy of sentinel lymph node was not required. Patients affected by ductal carcinoma in-situ were not included in this study. Adjuvant hormonal therapy or chemotherapy were allowed. In case of chemotherapy, radiation started one month after the completion of it.

Treatment {#Sec4}
---------

Radiation therapy consisted of 35 Gy delivered in 7 daily fractions, 5 Gy/fraction. At least three radio-opaque fiducial markers (surgical clips) were placed in the tumor bed at the time of surgery \[[@CR9]\]. Treatment planning for radiation was performed by immobilizing patients in supine position with the Quest Breastboard (Q-Fix System). All patients underwent a complete free breathing computed tomography (CT) simulation to include all the organs at risk (OAR), according to the RTOG 0413 protocol \[<http://www.rtog.org/members/protocols/0413/0413.pdf>\]. The CT simulation was performed not before two months following surgery. The clinical target volume (CTV) consisted of the lumpectomy cavity, identified by the surgical clips, uniformly expanded by 10 mm, limited to 5 mm from the skin surface and 5 mm from the lung--chest wall interface. The planning target volume (PTV) was calculated from the CTV using uniform three-dimensional expansion of 5 mm. PTV for evaluation (PTV-EVAL) is the structure used for dose-volume histogram (DVH) constraints and analysis; it is limited to exclude the part outside the ipsilateral breast and the first 5 mm of tissue under the skin and excluding the PTV expansion beyond the posterior extent of breast tissue. Radiation therapy was delivered to the PTV using three dimensional conformal fields, adopting the "field within a field" technique (forward Intensity Modulated Radiation Therapy technique) to improve dose homogeneity within the PTV and dosimetric coverage, as previously described \[[@CR10]\]. Dose calculation with tissue inhomogeneity correction was used. All treatments were developed using the Eclipse treatment planning system (Varian Medical Systems, Palo Alto, CA, USA), using multiple planar and non-coplanar 6-MV photon beams. Fig. [1](#Fig1){ref-type="fig"} shows a typical dose distribution. After a treatment plan was approved, digitally reconstructed radiographs (DRRs) were constructed to show each fiducial marker. Radiotherapy treatment commenced 3 to 4 weeks after simulation. The treatment was delivered by a Trilogy linear accelerator equipped with a kV on-board imager system and a 120-leaves Millennium multi-leaf collimator (Varian Medical Systems).Fig. 1Dose distribution for a partial breast irradiation plan (upper-outer quadrant of the left breast)

Follow-up and statistics {#Sec5}
------------------------

Patients were seen at regular intervals to determine the presence of symptoms, and physicians evaluated toxicity by Common Toxicity Criteria of Adverse Events, version 3.0. Follow-up visits for the evaluation of toxicity occurred 1, 3, 6 and 12 months from the completion of PBI for the first year, and then once a year. Cosmesis was assessed using the Harvard scale. Dosimetric parameters from the subgroup with and without Grade 2 or greater radiation induced breast fibrosis were compared using a two-tailed Student's *t* test; statistical significance was claimed for *p* \< 0.05.

Results {#Sec6}
=======

In the study period, 75 patients were enrolled. Two patients were lost at follow-up, therefore the analysis was conducted on 73 patients. Patient and tumor characteristics are reported in Table [1](#Tab1){ref-type="table"}. The median follow-up was of 40 months (range, 7--60 months).Table 1Patient and tumor characteristicsAge, years median70 range61--85Performance Status sec. ECOG 0--166 2--37Side Right breast41 Left breast32Histology Invasive Ductal Carcinoma67 Invasive Lobular Carcinoma6Tumor dimension, cm median1.2 range0.5--3.0T stage T167 T26N stage N053 N1mic8 N1a2 Nx10Estrogen Receptor status positive70 negative3Adjuvant therapy hormonal therapy alone47 chemotherapy alone0 chemotherapy and hormonal therapy3 none23

The proposed fractionation regimen was well tolerated. No Grade 3 toxicity was documented. Two (2.7%) patients experience Grade 2 erythema one month after PBI. Four (5.5%) patients developed Grade 1 skin hyperpigmentation. Ten (13.7%) patients had Grade 1 subcutaneous toxicity represented by a mild increased density at palpation of the irradiated tissue.

Late toxicity was assessable for all the treated patients. Two (2.7%) patients developed Grade 2 pain 6 months after PBI. Four (5.5%) patients developed asymptomatic fat necrosis, diagnosed at mammography. Grade 2 fibrosis was observed in 5 patients (6.7%). No cardiovascular events were documented. Cosmetic results were judged "good/excellent" in 69 patients (93%), and "poor" in 6 (7%).

No correlation was found between early and late toxicity and the type of adjuvant systemic therapy (no therapy vs. hormonal therapy vs. chemotherapy). No statistical correlation between dosimetric parameters and toxicity was found (Table [2](#Tab2){ref-type="table"}). In particular, patients who developed Grade 2 radiation fibrosis had not higher radiation volumes to the untreated normal breast (UNB) than those without fibrosis (Table [3](#Tab3){ref-type="table"}).Table 2Dosimetric data (mean values) of patients with and without Grade 2 radiation fibrosisRF (−)RF (+)*P* valuePTV_EVAL dimension119 ml108 ml*p* = n.s.PTV_EVAL/UNB ratio10.6%8.7%*p* = n.s.PTV_EVAL V95%97.0%94.5%*p* = n.s.Mean PTV_EVAL Dose35.2 Gy35.2 Gy*p* = n.s.Heart for Left Located Tumors V5%5.8%- D2 cc (gy)2.5 Gy*p* = n.s.Heart for Right Located Tumors V5%1.2%4.7%*p* = n.s.  D2cc (Gy)1.4 Gy1.3 GyIpsilateral Lung  V15%18.3%17.1%*p* = n.s.  V30%3.5%4.2%  V60%0.7%0.9%Controlateral Lung  V3%less than 1%less than 1%*p* = n.s.Controlateral Breast  V3%less than 1%less than 1%*p* = n.s.Thyroid  V3%less than 1%less than 1%p = n.s.*Abbreviations: RF* Radiation fibrosis, *UNB* Uninvolved normal breast, *N.s.* not significant Table 3Uninvolved normal breast dosimetric parameters (mean values) of patients with and without Grade 2 radiation fibrosisUNBRF (−)RF (+)*P* value*v5*75%80%*p* = n.s.*v10*69%74%*p* = n.s.*v15*62%64%*p* = n.s.*v20*54%55%*p* = n.s.*v25*49%51%*p* = n.s.*v30*45%48%*p* = n.s.*v35*42%45%*p* = n.s.*v40*39%41%*p* = n.s.*v45*35%37%*p* = n.s.*v50*32%33%*p* = n.s.*v55*29%30%*p* = n.s.*v60*27%26%*p* = n.s.*v65*25%23%*p* = n.s.*v70*23%21%*p* = n.s.*v75*21%19%*p* = n.s.*v80*19%17%*p* = n.s.*v85*17%16%*p* = n.s.*v90*15%14%*p* = n.s.*v95*12%11%*p* = n.s.*v100*6%6%*p* = n.s.*v105*0.2%0.2%*p* = n.s.*Abbreviations: UNB* uninvolved normal breast, *RF* radiation fibrosis, *N.s.* not significant

One patient experienced a local relapse 36 months after the end or radiotherapy, and subsequently underwent radical mastectomy. Local control rate at 5 years was 98%. One patient relapse distantly 3 months after radiotherapy, corresponding to a 5-year distant metastases-free survival rate of 96.7%. This patient died of disease 24 months later; the 5-year overall survival was 98.5%.

Discussion {#Sec7}
==========

In PBI, particularly in the United States, the most commonly used fractionation scheme includes 38.5 Gy delivered in a twice-daily administration. This is based on large, robust and reproducible data, supported both from single institution experiences and from large cooperative groups including the RTOG. Specifically, the RTOG 0319 was a phase II study aiming to evaluate the toxicity of three-dimensional conformal PBI, delivering 10 fractions of 3.85 Gy, twice daily over 5 days \[[@CR3]\]. With a median follow-up of 4.5 years only 2 (4%) Grade 3 toxicities were observed. This fractionation and technique were subsequently adopted in the NSABP B39/RTOG 0413 phase III trial, comparing standard whole breast radiation therapy versus partial breast irradiation including the external beam technique \[<https://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0413>\], and also by other large randomized studies \[<https://clinicaltrials.gov/ct2/show/NCT00282035>\].

The reason for adopting a one-fraction per day regimen is based on patient preference. A recent study reported survey data describing patient's breast radiation preferences \[[@CR11]\]. Of the 1807 women 70% preferred once-daily radiation therapy for 10 days compared with 30% who preferred the twice-daily option. Interestingly, the multivariate analysis showed that older women were more likely to prefer 10 days of once daily treatment. Moreover, a major factor influencing women's preference for whole breast irradiation over PBI was likely an aversion to twice-a-day treatment. The authors stated that they believe that their observations support the testing of novel once-daily PBI strategies in clinical trials.

We conducted a phase II prospective study to explore the toxicity profile of a novel fractionation scheme for PBI, consisting of 35 Gy delivered in 7 daily fractions. Using the linear quadratic model and the BED equation derived from this model, assuming an α/β ratio of 4 Gy, as suggested by experiments involving irradiation of human breast cancer cell lines, this prescription would be equivalent to 55.8 Gy in a standard 2-Gy fractionation \[[@CR12], [@CR13]\]. These calculations assumed that full repair takes place during the 24-h interval between fractions. In addition, because the hypofractionated regimen also represents an accelerated protocol in which the total dose is delivered in only 7 days, less tumor proliferation is expected to take place compared with that occurring during the standard treatment.

The recent implementation of normal tissue complication probability (NTCP) model for radiation induced fibrosis after PBI supports the hypothesis that this radiation schedule would be well tolerated \[[@CR7], [@CR8]\]. According to the model predictions, the present fractionation scheme (35 Gy in 7 fractions) should lead to the same incidence of fibrosis as the previous one, consisting of 40 Gy in 10 daily fractions \[[@CR6]\]. Congruent with our hypothesis, we documented that the incidence of Grade 2 fibrosis was of 6.7%. The Grade 2 fibrosis reported with the previous fractionation of 40 Gy in 10 fractions was 5.9% \[[@CR6]\].

The low toxicity profile reported in the present study is comparable with the results of other experiences adopting daily fraction schedules for PBI. Investigators at the New York University reported the outcome of 47 patients treated in prone position with 30 Gy at 6 Gy/fraction, delivered in 5 fractions within 10 days; with a median follow-up of 18 months they reported only late Grade 1 toxicity \[[@CR14]\]. Researchers from the University of Florence recently published their institutional phase III randomized trial, comparing whole breast irradiation vs. external beam PBI consisting of 30 Gy in 5 daily fractions \[[@CR15]\]. The PBI group presented significantly better results considering acute and late toxicity, and no Grade 2 or higher toxicities were observed in this group.

Conclusions {#Sec8}
===========

In conclusion, we showed that a 7 fractions schedule for PBI is safe, although a longer follow-up is needed to further ascertain late toxicity, and in particular late fibrosis. Based on the data reported in the present paper, we will continue our research in the direction of reducing the number of fractions for external beam PBI. We are now enrolling patients in a phase II trial designed to deliver 28 Gy in only 4 daily fractions.
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